Form 4: United Therapeutics Insider Trades Common Stock

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported significant transactions involving common stock and stock options on March 31, 2026.

Summary

• Martine A. Rothblatt, Chairperson & CEO and Director of United Therapeutics Corp, engaged in a series of transactions on March 31, 2026.
• These transactions included the acquisition of 9,500 shares of common stock at $146.03 per share, and the disposal of 805 shares at an average price of $582.19, among other disposals.
• The disposals were part of a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which continues until the exercise of 1,734,410 stock options or December 31, 2026.
• Rothblatt also reported transactions related to stock options, including the exercise of options and a gift of stock options from a trust to a family trust.
• Following these transactions, Rothblatt's beneficial ownership of common stock is detailed, including direct holdings and indirect holdings through trusts and by spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider transactions executed under a pre-arranged plan rather than a significant shift in the executive's outlook on the company's future.

Positives

• Acquisition of 9,500 shares of common stock at a price significantly lower than the disposal prices, indicating potential for future gains.
• The use of a 10b5-1 trading plan demonstrates a structured and pre-determined approach to managing stock transactions, often viewed positively for its adherence to compliance.
• The reporting person continues to hold a substantial number of shares indirectly through various trusts and directly, indicating continued investment in the company.

Negatives

• Significant disposal of common stock, totaling thousands of shares across multiple transactions, which could be interpreted as a reduction in direct holdings.
• The disposal prices, while higher than the acquisition price of the 9,500 shares, represent sales at prices that may be near market highs, potentially missing further upside.

Risks

• The 10b5-1 trading plan has an expiration date of December 31, 2026, or upon exercise of 1,734,410 stock options, creating a timeframe for future transactions.
• Stock options with exercise prices ranging from $117.76 to $135.42 are held, with some becoming exercisable in the near future, potentially leading to further sales.
• The gifting of stock options from one trust to another, while not a sale, represents a transfer of potential future equity.

Future Outlook

The 10b5-1 trading plan is set to continue until December 31, 2026, or until 1,734,410 stock options are exercised, indicating potential for further stock transactions within this period. Some stock options are set to expire in March 2027.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the biotechnology and pharmaceutical sectors, where executive compensation often includes significant stock option grants. The use of 10b5-1 plans is common practice for executives to diversify holdings while adhering to insider trading regulations.

Related Party Transactions

• A stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and immediate family members are beneficiaries. This gift was based on a formula using a valuation conducted on April 1, 2026.

Stakeholder Impact

• Shareholders may observe a reduction in the reporting person's direct holdings, though indirect holdings remain substantial.
• Employees may see the executive's continued engagement with the company's stock as a positive sign, despite the sales.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2026, or until 1,734,410 stock options are exercised.
• Certain stock options expire on March 15, 2027, and March 17, 2027.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, 10b5-1 Plan, United Therapeutics, UTHR, Martine Rothblatt, SEC Filing